A review of the presentation by Professor David Cunningham (pictured), London, UK. The risk profile of rectal tumours varies with the position and profile of the disease. David… read more.
A review of the presentation by Dermot O’Toole (pictured), Trinity College, Dublin. The incidence of Neuroendocrine tumours (NETs) has increased in recent years. The incidence is higher in… read more.
Dominik Modest, University Hospital, Grosshadern, Munch, Germany. Overall survival (OS) in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) who received first-line treatment with FOLFIRI plus… read more.
Review of the presentation by HJ Schmoll EORTC GI Group. [Preoperative chemoradiotherapy with capecitabine and oxaliplatin vs capecitabine alone in locally advanced rectal cancer: response to the local treatment… read more.
A review of the presentation by Rene Adam MD (pictured). There has been considerable progress in the overall survival of patients with colorectal cancer taking chemotherapy.
A review of the presentation by Sabine Tejpar. The KRAS (codon 12,13) is a validated predictive biomarker in mCRC, it is essential to determine diagnosis and required prior… read more.
A review of the presentation by Volker Heinemann (pictured). The decision on first line treatment in mCRC matters because the number of patients benefitting from therapy diminishes with… read more.
by Pam Harrison – MSI status has clear prognostic value in stage II CRC Julien Taieb, MD, PhD, University of Paris Descartes, Paris, France Microsatellite instability (MSI), a… read more.
We ask Professor Heinz-Josef Lenz, Professor of Medicine, Associate Director Clinical Research what he thinks is going to be the next big thing in colorectal cancer for the… read more.
Accurate, robust and simple method of identification has potential benefits to patients, hospitals and health services around the world.
by Bruce Sylvester – Nine thousand clinicians gathered at the 2013 annual meeting of the European Association for the Study of the Liver/International Liver Congress in Amsterdam on… read more.
Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
